Literature DB >> 27499963

The diagnostic utility and tendency of the soluble receptor for advanced glycation end products (sRAGE) in exudative pleural effusion.

Yun Su Sim1, Dong Gyu Kim1, Tae Rim Shin1.   

Abstract

BACKGROUND: The soluble receptor for advanced glycation end products (sRAGE) may have an inflammatory or homeostatic function in lung tissue. The aim of this study was to assess the usefulness of sRAGE as a diagnostic marker for exudative pleural effusions, which are common manifestations of a variety of diseases.
METHODS: Patients with an undiagnosed pleural effusion were prospectively enrolled between January 2013 and January 2015. Samples of blood and pleural fluid were centrifuged and the supernatant stored at -70 °C. The levels of sRAGE in serum and pleural fluid were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
RESULTS: In total 47 patients, 21 patients were diagnosed with a tuberculous effusion, and the groups diagnosed with parapneumonic or malignant effusions comprised 13 patients each. The serum sRAGE levels for tuberculosis were significantly elevated [median, 1,291 pg/mL; interquartile range (IQR), 948-1,711 pg/mL] when compared with those for both pneumonia (median, 794 pg/mL; IQR, 700-1,255 pg/mL) and lung cancer (median, 886 pg/mL; IQR, 722-1,285 pg/mL) (P=0.029). The pleural sRAGE levels for pneumonia (median, 1,763 pg/mL; IQR, 1,262-4,431 pg/mL) were lower than those for both tuberculosis (median, 5,081 pg/mL; IQR, 3,300-6,004 pg/mL) and lung cancer (median, 4,936 pg/mL; IQR, 3,282-7,018 pg/mL) (P=0.009) The receiver operating characteristic (ROC) curve analysis selected 896 pg/mL as the best cutoff value in the sRAGE serum level for tuberculosis [sensitivity, 86%; specificity 58%; area under the curve (AUC) =0.727, P=0.008]. For the pleural effusion sRAGE level, the ROC curve analysis selected 2,231 pg/mL as the best cutoff value for pneumonia (sensitivity, 91%; specificity, 62%, AUC =0.792, P=0.002).
CONCLUSIONS: Among patients with exudative effusion, pleural and serum sRAGE measurements may be useful supportive diagnostic tools in the evaluation of ambiguous pleural effusion. Furthermore, the behavior of sRAGE in the serum and pleural fluid of various pulmonary diseases suggests that sRAGE may be linked to the chronic process of lung damage and inflammation rather than acute bacterial infection.

Entities:  

Keywords:  Pleural effusion; receptor for advanced glycation end products (RAGE); tuberculosis

Year:  2016        PMID: 27499963      PMCID: PMC4958863          DOI: 10.21037/jtd.2016.05.94

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  Clinical practice. Pleural effusion.

Authors:  Richard W Light
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

Review 2.  RAGE in inflammation: a new therapeutic target?

Authors:  Angelika Bierhaus; David M Stern; Peter P Nawroth
Journal:  Curr Opin Investig Drugs       Date:  2006-11

3.  Plasma levels of soluble receptor for advanced glycation end products in patients with acute respiratory distress syndrome.

Authors:  Weili Gu; Zhihua Xu; Feng Qi; Zhihui Sang; Chunhua Wang; Feng Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  RAGE: a single receptor fits multiple ligands.

Authors:  Günter Fritz
Journal:  Trends Biochem Sci       Date:  2011-10-19       Impact factor: 13.807

5.  Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients.

Authors:  Matthieu Jabaudon; Emmanuel Futier; Laurence Roszyk; Elodie Chalus; Renaud Guerin; Antoine Petit; Segolene Mrozek; Sebastien Perbet; Sophie Cayot-Constantin; Christian Chartier; Vincent Sapin; Jean-Etienne Bazin; Jean-Michel Constantin
Journal:  Crit Care Med       Date:  2011-03       Impact factor: 7.598

6.  Receptor for advanced glycation end products is protective during murine tuberculosis.

Authors:  Marieke A D van Zoelen; Catharina W Wieland; Gerritje J W van der Windt; Sandrine Florquin; Peter P Nawroth; Angelika Bierhaus; Tom van der Poll
Journal:  Mol Immunol       Date:  2012-06-13       Impact factor: 4.407

Review 7.  The receptor for advanced glycation end products (RAGE) and the lung.

Authors:  Stephen T Buckley; Carsten Ehrhardt
Journal:  J Biomed Biotechnol       Date:  2010-01-19

8.  Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer.

Authors:  R Jing; M Cui; J Wang; H Wang
Journal:  Neoplasma       Date:  2010       Impact factor: 2.575

9.  S100A12 and soluble receptor for advanced glycation end products levels during human severe sepsis.

Authors:  Ahmed Achouiti; Dirk Föll; Thomas Vogl; Jan W O van Till; Pierre-François Laterre; Thierry Dugernier; Xavier Wittebole; Marja A Boermeester; Johannes Roth; Tom van der Poll; Marieke A D van Zoelen
Journal:  Shock       Date:  2013-09       Impact factor: 3.454

Review 10.  RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation.

Authors:  Louis J Sparvero; Denise Asafu-Adjei; Rui Kang; Daolin Tang; Neilay Amin; Jaehyun Im; Ronnye Rutledge; Brenda Lin; Andrew A Amoscato; Herbert J Zeh; Michael T Lotze
Journal:  J Transl Med       Date:  2009-03-17       Impact factor: 5.531

View more
  2 in total

1.  ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies.

Authors:  Der-Yuan Chen; Yen-Hsiang Huang; Yi-Ming Chen; Jeremy J W Chen; Tsung-Ying Yang; Gee-Chen Chang; Kuo-Tung Tang
Journal:  Lupus Sci Med       Date:  2021-11

Review 2.  The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries.

Authors:  Mitra Salehi; Shahin Amiri; Dariush Ilghari; Lawahidh Fadhil Ali Hasham; Hossein Piri
Journal:  Indian J Clin Biochem       Date:  2022-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.